Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2025-10-13 Interim / Quarterly Rep…
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Q2 26 Cxbladder Volumes Weaken After Coverage Loss
Interim / Quarterly Report Classification · 95% confidence The document is an investor update reporting quarterly operational and sales data for Q2 2026, including test volumes, sales force efficiency, and clinical study updates. It contains substantive financial and operational data for a quarter shorter than a full fiscal year. It is not a brief announcement or a certification, nor is it a full annual report. The content aligns with an Interim / Quarterly Report (IR) as it provides comprehensive financial and business performance information for a quarter. Q2 2026
2025-10-13 English
Q2 26 Cxbladder Volumes Weaken After Coverage Loss 13 pages 1.3MB
Investor Presentation Classification · 90% confidence The document is an investor update from Pacific Edge dated October 2025, covering Q2 26 test volumes and operational updates. It includes detailed financial and operational data such as test volumes, sales force efficiency, and Medicare reimbursement status. The content is comprehensive and includes management commentary, operational metrics, and outlook information. It is not a brief announcement or a simple press release but a detailed report aimed at investors. The document does not appear to be a full Annual Report (10-K) or an Interim/Quarterly Report (IR) with full financial statements, but rather an investor update with substantive financial and operational data. Given the detailed operational and financial update nature, this fits best as an Investor Presentation (IP) or possibly a Management Report (MDA). However, since it is titled as an "Investor Update" and includes detailed operational and strategic information, the best fit is Investor Presentation (IP).
2025-10-13 English
Notification of cessation of securities - PEB 4 pages 14.7KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for Pacific Edge Limited, including the number of securities ceased, reasons for cessation, and updated issued capital figures. It is a regulatory announcement related to changes in the company's issued capital but does not contain financial statements or detailed financial performance data. The document length is 3999 characters, which is relatively short and focused on a specific capital change event. This fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes such as cessation of securities.
2025-10-13 English
Application for quotation of securities - PEB 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard application for quotation of securities on the ASX. It details the issuance and quotation of securities resulting from options exercised or convertible securities converted. The document includes specifics about the securities, issue dates, and the number of securities to be quoted. This type of filing is related to share issuance and capital changes rather than financial results, management changes, or regulatory announcements. Therefore, it fits the category of Share Issue/Capital Change filings.
2025-10-13 English
NZX Capital Change Notices 4 pages 820.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Capital Change Notice' and contains detailed information about changes in the capital structure of Pacific Edge Limited, including lapsing of options, exercise of options, issuance of ordinary shares, and related percentages of total shares. It includes issuer information, class of financial product, ISIN, dates of issue/acquisition/redemption, and authority for the announcement. The content focuses on capital changes such as option lapses and share issuances, which are typical of announcements related to capital structure changes. There is no indication that this is a full financial report, earnings release, or regulatory certification. The document is substantive and not merely an announcement of a report. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2025-10-13 English
Novitas Proposes Expert Panel in Response to 2025 AUA Guide
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a Medicare Administrative Contractor (MAC) Novitas proposing an expert panel to consider coverage for tests related to the 2025 update of the American Urological Association (AUA) guideline. It discusses policy development and the convening of a Contractor Advisory Committee (CAC) but does not contain financial data, earnings, or detailed report content. The document is relatively short (3594 characters) and serves as a regulatory or corporate update rather than a financial report or detailed filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about policy and coverage considerations without substantive financial or governance data.
2025-09-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.